Company: BIAF
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024163
Chunk: 27

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 27
---
 304,125  
    $6.95  
     3.90  
     — 

As
of June 30, 2025, there was no unrecognized compensation cost related to non-vested stock options.

The
following table summarizes restricted stock award activity under the 2014 Plan and 2024 Plan:

SUMMARY OF RESTRICTED STOCK AWARD

    Number of  

    As of June 30, 2025 

    restricted  stock awards  (RSA)  
    Weighted-  average  grant price  
    FMV on  grant date  
    Vested  number  of RSA  
    Unvested  number  of RSA 
  
    Balance at December 31, 2024 
     1,326,861  
    $1.99  
    $2,636,259  
     1,215,592  
     171,671 
  
    Granted 
     258,398  
     0.81  
     208,559  
     121,408  
     136,990 
  
    Forfeited 
     (25,721) 
     0.81  
     (20,834) 
     —  
     (25,721)
  
    Balance at June 30, 2025 
     1,559,538  
    $1.81  
    $2,823,984  
     1,139,496  
     282,940 

During
the three months ended June 30, 2025, the Company issued restricted stock awards (“RSAs”) for 5,000 shares of Common Stock
to employees, non-employees, and the board of directors. The shares vest in equal monthly installments over terms of immediately and
up to three years, subject to the employees and non-employees providing continuous service through the vesting date. During the six months
ended June 30, 2025, 172,660 shares vested from RSAs granted prior to January 1, 2025, and 121,408 shares vested from RSAs granted during
the six months ended June 30, 2025.

    17

Note
14. WARRANTS

The
Company’s outstanding Common Stock warrants are a combination of equity and liability classified. As of June 30, 202